---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-101414"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-08-01T23:59:59+00:00"
generated_at: "2026-05-17T21:59:50.257912+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation; no material new data disclosed

## Summary
- Updated corporate presentation filed August 1, 2025; no new clinical data or financial guidance disclosed.
- Pipeline includes [212Pb]VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-α.
- Presentation notes sustained anti-tumor activity and tolerability for NET trial; no quantitative updates.
- Pre-targeting platform and supply chain infrastructure highlighted as key differentiators.

## SEC filing metadata
- accession: 0000950170-25-101414
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025101414/0000950170-25-101414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025101414/catx-20250801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-101414
- JSON: https://secwatch.observer/filing/0000950170-25-101414.json
- Plain text: https://secwatch.observer/filing/0000950170-25-101414.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.